Digital Measures of Neuropsychological Tests

Rationale: There is a need for digital neuropsychological tests. Philips created a digital
Cognitive Dx platform with neuropsychological tests that are derived from digitizing existing
tests. Digital tests make automatic scoring and analysis possible. In order to exploit the full
value to the Cognitive Dx platform we need to develop state-of- the-art algorithms to both
automatically detect relevant features but also to classify these and provide automatic
scoring.

Objective: The main objective of the study is to collect digital data for the tests that are
currently hosted on the Cognitive Dx platform and to use this data to develop and refine the
existing algorithms that automatically score the test. Secondary objectives are comparing
specific digital measures, or combination of digital measures, that are generated by the
algorithms and to discover if these are different for Early Stage Alzheimer Disease (AD)
patients as compared to healthy individuals and the evaluation of the usability of the digitized
test platform in the healthy and AD population.

Study design: The digitized tests will be administered to 80 healthy participants and 80 AD
patients. The participants will be recruited by the company Silverbrains. They will recruit AD
patients and their partner or relative (as healthy participants) from a proprietary database of
elderly individuals. The study requires a single home visit with a maximum study duration of
1,5 hour for the partner or relative and 2 hours for the AD patient.

Study population: This study will include 80 healthy participants and 80 Early Stage
Alzheimer Disease patients.

Main study parameters/endpoints: The main study parameters are the algorithmic
outcome of the automated scoring of the tests and the manual scoring of the tests.
Nature and extent of the burden and risks associated with participation, benefit and
group relatedness: There are negligible risks of using the software, Ipad and laptop in the
current set up. The research will be performed by a trained psychologist, who has experience
in conducting neuropsychological tests with AD patients. The duration of participation is
limited to 1,5 hours for the healthy participants and 2 hours for AD patients. To mitigate the
risk of fatigue in patients with AD we will split the 2 hours into two equal halves. The patients
will rest for 1,5 hours between each halve. There will only be one home visit required. There
is no direct benefit to the participants, but they will contribute and enable the development of
a product which can contribute to the improvements of neuropsychological tests and improve
the existing diagnostics of cognition. In conclusion, the risks associated with participation can
be considered negligible and the burden minimal.

Day 1= Day of questionnaire completion

The digitized tests will be administered to 80 Early Stage Alzheimer Disease (AD) patients and 80 healthy participants (their partner or relative) and. The study requires a single visit to the patients' home with a maximum duration of 1.5 hour for the partner or relative and 2 hours for the AD patient.



Participants will complete 10 digital neuropsychological tests, the cognitive screening questionnaire and the usability questionnaire.